Travere Therapeutics, Inc.
TVTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.09 | -0.11 | 0.67 |
| FCF Yield | -24.65% | -48.17% | -16.01% | -2.10% |
| EV / EBITDA | -6.46 | -3.11 | -5.63 | -10.59 |
| Quality | ||||
| ROIC | -69.27% | -63.02% | -59.79% | -30.38% |
| Gross Margin | 96.68% | 92.12% | 95.96% | 97.10% |
| Cash Conversion Ratio | 0.74 | 0.74 | 0.56 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 28.67% | 3.28% | -17.97% | -9.07% |
| Free Cash Flow Growth | -5.31% | -49.83% | -451.21% | 76.05% |
| Safety | ||||
| Net Debt / EBITDA | -1.29 | -1.06 | -1.15 | -0.52 |
| Interest Coverage | -28.96 | -34.25 | -29.04 | -10.13 |
| Efficiency | ||||
| Inventory Turnover | 1.25 | 1.22 | 0.98 | 0.52 |
| Cash Conversion Cycle | -774.56 | -975.31 | -998.78 | -704.58 |